We herein report a case of Guillain-Barré syndrome (GBS) after SARS-CoV-2 an infection. The affected person was an in depth contact with a SARS-CoV-2 affected person. Initially, she didn’t have any signs and quarantined at a resort. Dysgeusia and olfactory abnormality appeared at day 6 after testing constructive for an infection and disappeared by day 9.
Subsequently, the affected person developed numbness of the legs and arms, issue strolling, and dyspnea and was referred to our hospital. Her scientific examination confirmed generalized weak spot and hyporeflexia. A cerebrospinal fluid evaluation confirmed albuminocytological dissociation. Her nerve conduction research had been in keeping with demyelinating polyneuropathy. Intravenous immunoglobulin was administered primarily based on a analysis of GBS.

Telaprevir is a possible drug for repurposing towards SARS-CoV-2: computational and in vitro research

Drug repurposing is a vital method to the project of already authorised medication for brand spanking new indications. This system bypasses some steps within the conventional drug approval system, which saves time and lives within the case of pandemics. Direct appearing antivirals (DAAs) have repeatedly repurposed from treating one virus to a different.
On this research, 16 FDA-approved hepatitis C virus (HCV) DAA medication had been studied to discover their actions towards extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human and viral targets. Among the many 16 HCV DAA medication, telaprevir has proven one of the best in silico proof to work on each oblique human targets (cathepsin L [CTSL] and human angiotensin-converting enzyme 2 [hACE2] receptor) and direct viral targets (fundamental protease [Mpro]).
Furthermore, the docked poses of telaprevir inside each hACE2 and Mprofessional had been subjected to further molecular dynamics simulations monitored by calculating the binding free vitality utilizing MM-GBSA. In vitro evaluation of telaprevir confirmed inhibition of SARS-CoV-2 replication in cell tradition (IC50 = 11.552 μM, CC50 = 60.865 μM, and selectivity index = 5.27). Accordingly, primarily based on the in silico research and supported by the offered in vitro evaluation, we recommend that telaprevir could also be thought-about for therapeutic growth towards SARS-CoV-2.

Focusing on Intra-Viral Conserved Nucleocapsid (N) Proteins as Novel Vaccines towards SARS-CoVs

Extreme Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has brought on the worldwide pandemic of the Coronavirus illness in late 2019 (COVID-19). Vaccine growth efforts have predominantly been geared toward ‘Further-viral’ Spike (S) protein as vaccine autos however there are considerations relating to ‘viral immune escape’ since a number of mutations could allow the mutated virus strains to flee from immunity towards S protein. The ‘Intra-viral’ Nucleocapsid (N-protein) is comparatively conserved amongst mutant strains of coronaviruses throughout unfold and evolution.
Herein, we reveal novel vaccine candidates towards SARS-CoV-2 through the use of the entire conserved N-protein or its fragment/peptides. Utilizing ELISA assay, we confirmed that prime titers of particular anti-N antibodies (IgG, IgG1, IgG2a, IgM) had been maintained for a fairly lengthy length (> 5 months), suggesting that N-protein is a superb immunogen to stimulate host immune system and strong B cell activation.
We synthesized three peptides situated on the conserved areas of N-protein amongst CoVs. One peptide confirmed as a very good immunogen for vaccination as effectively. Cytokine arrays on post-vaccination mouse sera confirmed progressive upregulation of varied cytokines corresponding to IFN-γ and CCL5, suggesting that TH1 related responses are additionally stimulated.
Moreover, vaccinated mice exhibited an elevated reminiscence T cells inhabitants. Right here, we suggest an unconventional vaccine technique concentrating on the conserved N-protein in its place vaccine goal for coronaviruses. Furthermore, we generated a mouse monoclonal antibody particularly towards an epitope shared between SARS-CoV and SARS-CoV-2, and we’re presently creating the First-in-Class humanized anti-N-protein antibody to doubtlessly deal with sufferers contaminated by numerous CoVs sooner or later.

The SARS-CoV-2 spike protein is weak to average electrical fields

A lot of the ongoing tasks aimed on the growth of particular therapies and vaccines towards COVID-19 use the SARS-CoV-2 spike (S) protein as the principle goal. The binding of the spike protein with the ACE2 receptor (ACE2) of the host cell constitutes the primary and key step for virus entry.
Throughout this course of, the receptor binding area (RBD) of the S protein performs a necessary function, because it incorporates the receptor binding motif (RBM), accountable for the docking to the receptor. Up to now, largely biochemical strategies are being examined with the intention to forestall binding of the virus to ACE2.
Right here we present, with the assistance of atomistic simulations, that exterior electrical fields of simply achievable and average strengths can dramatically destabilise the S protein, inducing long-lasting structural harm. One hanging field-induced conformational change happens on the degree of the popularity loop L3 of the RBD the place two parallel beta sheets, believed to be accountable for a excessive affinity to ACE2, bear a turn into an unstructured coil, which displays nearly no binding prospects to the ACE2 receptor.
We additionally present that these extreme structural modifications upon electric-field software additionally happen within the mutant RBDs akin to the variants of concern (VOC) B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil). Remarkably, whereas the structural flexibility of S permits the virus to enhance its likelihood of getting into the cell, additionally it is the origin of the stunning vulnerability of S upon software of electrical fields of strengths a minimum of two orders of magnitude smaller than these required for damaging most proteins.
Our findings recommend the existence of a clear bodily technique to weaken the SARS-CoV-2 virus with out additional biochemical processing. Furthermore, the impact may very well be used for an infection prevention functions and likewise to develop applied sciences for in-vitro structural manipulation of S. For the reason that technique is basically unspecific, it may be appropriate for software to different mutations in S, to different proteins of SARS-CoV-2 and basically to membrane proteins of different virus sorts.

Airborne SARS-CoV-2 surveillance in hospital surroundings utilizing high-flowrate air samplers and its comparability to floor sampling

Dependable strategies to detect the presence of SARS-CoV-2 at venues the place folks collect are important for epidemiological surveillance to information public coverage. Communal screening of air in a extremely crowded house has the potential to supply early warning on the presence and potential transmission of SARS-CoV-2 as recommended by research early within the epidemic.
As hospitals and public services apply various levels of restrictions and laws, you will need to present a number of methodological choices to allow environmental SARS-CoV-2 surveillance beneath completely different circumstances. This research assessed the feasibility of utilizing high-flowrate air samplers mixed with RNA extraction package designed for environmental pattern to carry out airborne SARS-CoV-2 surveillance in hospital setting, examined by RT-qPCR.
The success charge of the air samples in detecting SARS-CoV-2 was then in contrast with floor swab samples collected in the identical proximity. Moreover, constructive RT-qPCR samples underwent viral tradition to evaluate the viability of the sampled SARS-CoV-2.
The research was carried out in inpatient ward environments of a quaternary care college educating hospital in Singapore housing lively COVID-19 sufferers throughout the interval of February to Could 2020. Two sorts of wards had been examined, naturally ventilated open-cohort ward and mechanically ventilated isolation ward. Distances between the location of air sampling and the affected person cluster within the investigated wards had been additionally recorded.
No profitable detection of airborne SARS-CoV-2 was recorded when 50 L/min air samplers had been used. Upon growing the sampling flowrate to 150 L/min, our outcomes confirmed a excessive success charge in detecting the presence of SARS-CoV-2 from the air samples (72%) in comparison with the floor swab samples (9.6%). The constructive detection charge of the air samples together with the corresponding viral load may very well be related to the gap between sampling web site and affected person.

SARS Spike Antibody

24318-100ul 100ul
EUR 390

SARS Spike Antibody

20-abx137184
  • EUR 1052.00
  • EUR 1539.00
  • EUR 1720.00
  • 100 ug
  • 200 ug
  • 300 µg
  • Shipped within 5-10 working days.

SARS Spike Antibody

20-abx137200
  • EUR 1177.00
  • EUR 1887.00
  • EUR 2221.00
  • 100 ug
  • 200 ug
  • 300 µg
  • Shipped within 5-10 working days.

SARS-CoV spike protein Antibody

abx023139-100ug 100 ug
EUR 857
  • Shipped within 5-10 working days.

SARS-CoV spike protein Antibody

abx023143-100ug 100 ug
EUR 857
  • Shipped within 5-10 working days.

SARS-CoV Spike Protein

abx060655-1mg 1 mg
EUR 1692
  • Shipped within 5-10 working days.

Recombinant 2019-nCoV coronavirus Spike protein S1 subunit

Spike-191V 100ug
EUR 792
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to His tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

Recombinant 2019-nCoV coronavirus Spike protein S1 subunit

Spike-192V 100ug
EUR 792
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Human IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

Recombinant 2019-nCoV coronavirus Spike protein S1 subunit

Spike-193V 100ug
EUR 1610
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Mouse IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

Recombinant 2019-nCoV coronavirus Spike protein, S1+S2 ECD

Spike-194V 100ug
EUR 1610
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein (S1+S2 ECD) was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cell. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity.

anti-SARS spike glycoprotein antibody (clone 3A2)

65-101 50ug
EUR 296
Description: The anti-SARS spike glycoprotein antibody (clone 3A2) is available in Europe and for worldwide shipping via Gentaur.

Anti-SARS-CoV-2 Spike S1 Antibody

A3000-50 50 µg
EUR 419

Recombinant SARS Coronavirus Spike, GST-Tagged

DAG534 1mg
EUR 1556

Sars-Cov, Spike (Middle) Recom Protein

abx060656-1mg 1 mg
EUR 1692
  • Shipped within 5-10 working days.

SARS Associated Spike Mosaic S Protein

20-abx260156
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg
  • Shipped within 5-10 working days.

Mouse Monoclonal Anti-SARS Spike IgG

AB-17910 50 ug
EUR 469

Recombinant SARS Spike gp C Protein

VAng-Lsx0072-inquire inquire Ask for price
Description: SARS Spike glycoprotein C, recombinant protein from E. coli.

Recombinant 2019-nCoV coronavirus Spike protein S1 subunit receptor binding domain

Spike-19V 100ug
EUR 792
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit receptor binding domain (RBD) was fused to Mouse IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

Recombinant 2019-nCoV coronavirus Spike protein, S1 subunit, expressed in Baculovirus-Insect cells

Spike-195V 100ug
EUR 1610
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant 2019-nCoV coronavirus Spike protein, S2 ECD, expressed in Baculovirus-Insect cells

Spike-197V 100ug
EUR 1610
  • Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at +4 degrees Celsius before opening to recover the entire contents.
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein (S2 ECD) was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS Associated Spike Mosaic S(N)

7-07093 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S(N)

7-07094 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S(N)

7-07095 1000µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)

7-07096 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)

7-07097 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)

7-07098 1000µg Ask for price

Recombinant SARS Associated Spike Mosaic S©

7-07099 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S©

7-07100 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S©

7-07101 1000µg Ask for price

Sars-Cov, Spike (N-Term) Recom Protein

abx060657-1mg 1 mg
EUR 1873
  • Shipped within 5-10 working days.

SARS Associated Spike Mosaic S(M) Protein

20-abx260155
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg
  • Shipped within 5-10 working days.

SARS Associated Spike Mosaic S(N) Protein

20-abx260157
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg
  • Shipped within 5-10 working days.

Mouse Monoclonal Anti-SARS Spike Protein IgG

AB-15710 20 ug
EUR 408

Recombinant (E.Coli) SARS Associated Spike Mosaic S

RP-1422 100 ug
EUR 286

Recombinant (E.Coli) SARS Associated Spike Mosaic S

RP-1423 100 ug
EUR 286

Recombinant (E.Coli) SARS Associated Spike Mosaic S

RP-1424 100 ug
EUR 286

Recombinant Coronavirus Spike Protein (SARS-CoV S2)

P1519-10 10µg
EUR 156

Recombinant Coronavirus Spike Protein (SARS-CoV S2)

P1519-50 50µg
EUR 551

SARS-CoV-2 Spike RBD protein antibody pair 1

CSB-EAP33245 1 pair
EUR 750
  • The recommended concentrations for analysis performance are 1ug/ml for the capture antibody and 0.42ug/ml for the detection antibody, respectively. The optimal dilutions should be determined experimentally by the researcher.
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA.

Anti-SARS-CoV-2 Spike S1 Antibody (Clone# 4C6)

A3001-50 50 µg
EUR 419

Recombinant SARS Coronavirus Spike (C-term), GST-Tagged

DAG539 1mg
EUR 1556

Recombinant SARS-CoV Spike protein [GST] (37 kDa)

VAng-Wyb8620-inquire inquire Ask for price
Description: SARS-CoV C-terminal of the Spike protein (37 kDa), recombinant protein from E. coli, 1 mg/mL.

Recombinant SARS-CoV Spike protein [GST] (38 kDa)

VAng-Wyb8621-inquire inquire Ask for price
Description: SARS-CoV middle region of the Spike protein (38 kDa), recombinant protein from E. coli, 1 mg/mL.

Recombinant SARS Spike Protein (aa 1-1190) [His]

VAng-Lsx0063-inquire inquire Ask for price
Description: SARS Spike protein (aa 1-1190) [His], recombinant protein from HEK 293 cells.

Recombinant SARS Spike Mosaic Protein S (N-Terminal)

VAng-Lsx0073-inquire inquire Ask for price
Description: SARS spike mosaic protein S (N-terminal), recombinant protein from E. coli.

Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD)

P1533-10 10 µg Ask for price

Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD)

P1533-50 50 µg Ask for price

SARS Polyclonal Antibody

A53977 100 µg
EUR 570.55
Description: The best epigenetics products

Spike Glycoprotein Polyclonal Antibody

A57201 100 µg
EUR 570.55
Description: fast delivery possible

Spike Glycoprotein Polyclonal Antibody

A56214 100 µg
EUR 570.55
Description: kits suitable for this type of research

Recombinant Coronavirus SARS Associated Spike (N-terminal), GST-tagged

DAG547 1mg
EUR 1535

Recombinant (HEK) SARS Coronavirus Spike S1 protein (His-tag)

SARSS15-R-10 10 ug
EUR 347

Recombinant Coronavirus Spike Protein (SARS-CoV S1; His tag)

P1516-10 10µg
EUR 257

Recombinant Coronavirus Spike Protein (SARS-CoV S, His tag)

P1520-10 10µg
EUR 257

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)

P1540-10 10 µg
EUR 176

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)

P1540-50 50 µg
EUR 682

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)

P1541-10 10 µg
EUR 176

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)

P1541-50 50 µg
EUR 682

Recombinant Coronavirus Spike Protein (SARS-CoV-2; His tag)

P1528-10 10 µg Ask for price

Recombinant Coronavirus Spike Protein (SARS-CoV-2; His tag)

P1528-50 50 µg Ask for price

SARS Rabbit pAb

A13350-100ul 100 ul
EUR 308

SARS Rabbit pAb

A13350-200ul 200 ul
EUR 459

SARS Rabbit pAb

A13350-20ul 20 ul
EUR 183

SARS Rabbit pAb

A13350-50ul 50 ul
EUR 223

SARS Rabbit pAb

A6733-100ul 100 ul
EUR 308

SARS Rabbit pAb

A6733-200ul 200 ul
EUR 459

SARS Rabbit pAb

A6733-20ul 20 ul
EUR 183

SARS Rabbit pAb

A6733-50ul 50 ul
EUR 223

Polyclonal SARS Matrix Antibody

APG02976G 0.1 mg
EUR 659
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications:

Polyclonal SARS Matrix Antibody

APR11178G 0.1 mg
EUR 659
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications:

Recombinant SARS Coronavirus Spike S1 Protein (aa 1-667) [His]

VAng-Wyb7337-100g 100 µg
EUR 1747
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike S1 protein, recombinant protein.

Recombinant SARS Coronavirus Spike S1 Protein (aa 1-667) [His]

VAng-Wyb7337-20g 20 µg
EUR 628
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike S1 protein, recombinant protein.

Recombinant SARS Coronavirus Spike S1 Protein (aa 1-667) [His]

VAng-Wyb7337-50g 50 µg
EUR 1105
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike S1 protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [His]

VAng-Wyb7338-100g 100 µg
EUR 1747
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [His]

VAng-Wyb7338-20g 20 µg
EUR 628
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [His]

VAng-Wyb7338-50g 50 µg
EUR 1105
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [Fc]

VAng-Wyb7339-100g 100 µg
EUR 1747
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [Fc]

VAng-Wyb7339-20g 20 µg
EUR 628
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Recombinant SARS Coronavirus Spike (RBD) Protein (aa 306-527) [Fc]

VAng-Wyb7339-50g 50 µg
EUR 1105
Description: severe acute respiratory syndrome coronavirus (isolate:WH20) Spike protein, recombinant protein.

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant

P1530-10 10 µg
EUR 156

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant

P1530-50 50 µg
EUR 591

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant

P1547-10 10 μg
EUR 196

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant

P1547-50 50 μg
EUR 652

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant

P1555-10 10μg
EUR 196

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant

P1555-50 50μg
EUR 591

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant

P1531-10 10 µg Ask for price

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant

P1531-50 50 µg Ask for price

SARS Polyclonal Antibody, HRP Conjugated

A53978 100 µg
EUR 570.55
Description: kits suitable for this type of research

SARS Polyclonal Antibody, FITC Conjugated

A53979 100 µg
EUR 570.55
Description: fast delivery possible

SARS Polyclonal Antibody, Biotin Conjugated

A53980 100 µg
EUR 570.55
Description: reagents widely cited

Recombinant SARS Spike Mosaic S Protein (aa 408-470, 540-573)

VAng-Lsx0056-inquire inquire Ask for price
Description: Recombinant SARS-CoV Spike protein containing 408-470, 540-573 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique.

Recombinant Coronavirus Spike Protein (SARS-CoV S2; 408-470, 540-573)

P1518-10 10µg
EUR 156

Recombinant Coronavirus Spike Protein (SARS-CoV S2; 408-470, 540-573)

P1518-50 50µg
EUR 551

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S1), Recombinant

P1524-10 10 µg
EUR 277

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S2), Recombinant

P1525-10 10 µg
EUR 277

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant

P1529-10 10 µg Ask for price
The furthest distance from affected person with PCR-positive air samples was 5.5 m. The airborne SARS-CoV-2 detection was comparable between the 2 sorts of wards with 60%-87.5% success charge. Excessive prevalence of the virus was present in bathroom areas, each on surfaces and in air. Lastly, no profitable tradition try was recorded from the environmental air or floor samples.

LEAVE A REPLY

Please enter your comment!
Please enter your name here